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Background: The aim of this study was to investigate whether carotid intima media thickness (CIMT) is associated
with serum level of retinol- binding protein-4 (RBP4) and total and high molecular weight (HMW) adiponectin in
type 2 diabetes (T2DM) without clinical symptom of atherosclerotic disease.
Method: 101 type 2 diabetic patients (mean age, 53.63 ± 8.42 years) and 42 body mass index (BMI) matched
control (mean age 50.1 ± 8.4) were recruited. The CIMT was assessed by using B-mode ultrasonography, while
serum levels of RBP4 and total and HMW adiponectin were measured by using enzyme linked immunosorbant
assay (ELISA). Linear regression analysis was performed with CIMT as dependent variable and adipokines and cardio
metabolic risk factors as independent variables.
Result: The CIMT was higher in diabetic group compared to control group (p <0.05). The mean concentration of
RBP4 and total and HMW adiponectin did not differ between two groups.
Age (B= 0.44 P <0.05), blood pressure (B= 0.37 P=<0.05), waist circumference (B=−0.21 P <0.05) and TG (B=0.1 P <0.05)
were identified as independent predictors for CIMT in diabetic group, while RBP4 and adiponectin were not associated
with CIMT neither in diabetic group nor in control group.
Conclusion: In conclusion, the present study showed that serum levels of RBP4 or total and HMW adiponectin were not
potential predictors of CIMT in type 2 diabetic patients who exposed to this risk factor at least for nine years.
Keywords: Carotid intima media thickness, Adipokines, B mode ultrasonography, Enzyme linked immunosorbant assay
(ELISA), Type 2 diabetesIntroduction
The type 2 diabetes (T2DM) is one of the major risk fac-
tors of cardiovascular disease (CVD) which is in turn the
leading cause of death in these patients [1].
Therefore, one of the most important issues in the ma-
nagement of diabetes is to predict and prevent the develop-
ment of CVD [2]. The carotid intima- media thickness
(CIMT) is an independent predictor of future cardiovascu-
lar events and increased CIMT was recently suggested to
be significantly related to the presence and extent of* Correspondence: omidfar@tums.ac.ir; fakhrzad@tums.ac.ir
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reproduction in any medium, provided the orabnormal myocardial perfusion. Therefore the CIMT can
be used as a screening test in the diabetic patients who are
at risk of coronary artery disease (CAD) [3,4].
Recent studies have shown that adipose tissues secret a
number of various bioactive substances known as adipo-
kines which might affect insulin sensitivity or vascular func-
tion [5-8]. Of these adipokines, retinol binding protein-4
(RBP4) acts as a potential determinant of insulin resistance
and plays a role to induce sub clinical inflammation leading
to cardiovascular diseases in T2DM [7,9]. It was reported
that serum RBP4 levels were increased in individual with
obesity, impaired glucose tolerance, T2DM and even gesta-
tional diabetes [10-13].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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anti-inflammatory properties and suppresses various
mechanisms contributing to atherogenesis [14]. Accor-
ding to the literature plasma adiponectin may be deregu-
lated in disorders susceptible to atherosclerotic vascular
diseases, such as diabetes mellitus [15].
Increasing adiponectin by life style change and exer-
cise has been reported in diabetic patients but not in
healthy subject [16]. Regarding the relationship between
CIMT and these two adipokines a few information with
conflicting results have been published. Moreover the
place of these adipokines measurements as plasma mar-
kers to predict cardiovascular disease in diabetic patients
is not yet clear. Therefore this study was designed to in-
vestigate the associations between CIMT and RBP4 and
total and HMW adiponectin altogether in diabetic




The study samples included a total of 101 type 2 diabetic
patients (48 male and 53 female) with a mean age of
(53.6 ± 8.4 year) who were diagnosed according to the
world health organization criteria as two times fasting
blood glucose equal or greater than 126 mg/dl or use of
oral hypoglycemic agent. They were visited in a diabetes
outpatient clinic in Shariati Hospital of Tehran University
of Medical Sciences. The mean duration of diabetes was
(8.85 ± 6.24) years. All diabetic patients were on oral anti
diabetic agents and none of them were current or previous
smoker except nine. The control groups were selected
among healthy friends of diabetic patients who volun-
teered to participate in a medical and laboratory screening
examination, including 25 males and 20 females, with a
mean age of (50.1 ± 8.4 years). The inclusion criteria for
control group included healthy subject without diabetes
and known metabolic disease and did not take any medica-
tion. We collected information on lifestyle, medical history,
smoking and the use of medication by using questioners
(which were requested to fill out by all the participants) and
subsequent interview. Both groups were within the same
age interval and matched for BMI.
The diabetic cases who had clinical symptoms of
large vessel diseases including chest pain, abnormal
12-lead electrocardiography, history of myocardial in-
farction, cerebral infarction and claudication were
excluded. In addition for evaluating peripheral vascular
disease (PVD) ankle brachial pressure index (ABI) was
measured with a Doppler Ultrasound (France). The patients
with ABI less than 0.9 and more than 1.3 were excluded
[17]. Screening for microvascular complication was per-
formed as follows. Assessment of diabetic retinopathy as no
diabetic retinopathy, non proliferative retinopathy andproliferative diabetic retinopathy were performed by two
trained ophthalmologist. The subjects with proliferative ret-
inopathy were excluded. Renal dysfunction was assessed by
estimated glomerular filtration rate using the modification
of diet in renal disease equation (GFR-MDRD) [18]. For
evaluating neuropathy, vibratory sensation was examined
by placing a 128 hz diapason on the malleolar and the
radius of lower extremity and upper extremity respect-
ively. Vibratory sensation seems to be adversely affected
early in the pathogenesis of diabetic peripheral poly-
neuropathy [19]. The patients with vibration sensation loss
were excluded.
Protocol of the study was approved by ethics committee
of the Teheran University of Medical Sciences and a written
consent form with the required information was signed by
the participants prior to the study.
Methods
After at least 12 hours fasting, blood samples were col-
lected. Height, weight and resting blood pressure in a sit-
ting position were measured by the study attending nurse.
The BMI was measured by dividing the weight (kg) to
height (m2). Waist circumference defined as the minimal
abdominal circumference between the xiphoid process
and iliac crest.
Hypertension was defined as systolic blood pressure
(SBP) ≥ 140 mm/Hg or diastolic blood pressure (DBP)
≥ 90 mm Hg and or using anti-hypertensive medication in
the same session. The blood was transformed immediately
and kept at -80c C. Fasting plasma glucose (FPG), total
cholesterol and triglyceride were measured by commer-
cially available enzymatic reagents (Pars Azmoon, Tehran,
Iran) adapted to an Auto analyzer (Hitachi 902, Japan).
High density lipoprotein cholesterol (HDL-C) and low
density lipoprotein cholesterol (LDL-C) were assayed by
using turbidometric method (Pars Azmoon, Tehran, Iran).
Insulin was measured via ELISA using Monobind kit
(Denmark), with inter-assay and intra- assay coefficient
variation (CV) being 6.32% and 1.9% respectively. HbA1C
levels are measured by High-performance liquid chro-
matography (HPLC). Homeostasis model assessment
(HOMA) index was applied for the determination of the
insulin resistant according to the following equation:
HOMA index= fasting glucose (mg/dl) x fasting insulin
(μU/ml) / 405.
Serum RBP4 was measured using ELISA kit (AdipoGen,
Seoul, Korea). The total and HMW adiponectin were also
assessed using ELISA kit (Millipore, USA). Three samples
of known concentration (low, moderate and high) were
tested for both RBP4, the total and HMW adiponectin in
eight independent analytical runs to assess precision
within and between assays. The measured intra-assay
(CV) for low, moderate and high range of RBP4 were
3.5%, 2.0% and 3.7%, respectively, and the inter-assay were
Table 1 Clinical characteristics of diabetic group and
control group
Variables Cases Controls P Age
adjusted
sex (m/f) 101 (48/53) 42 (19/23)
Age (years) 53.6 ± 8.4 50.1 ± 8.4 <0.05*
BMI (kg/m2) 27.7 ± 4.1 28.7 ± 4.6 0.37 0.26
Waist
circumference (cm)
94.0 ± 10.8 93.5 ± 10.3 0.81 0.89
Duration of
Diabetes (years)
8.8 ± 6.2 - -
SBP (mm Hg) 132.9 ± 17.3 129.1 ± 13.6 0.19 0.39
DBP (mm Hg) 77.0 ± 9.7 78.7 ± 11.2 <0.05* 0.46
FPG (mg/dl) 165.1 ± 62.2 97.8 ± 10.5 0.001* 0.001*
HbA1C 7.9 ± 1.7 5.3 ± 0.6 0.001* 0.001*
Fasting Insulin 8.6 ± 6.6 8.5 ± 4.9 0.95 0.76
HOMA-IR 3.5 ± 2.7 2.1 ± 1.2 0.001* 0.001*
Triglyceride 195.3 ± 108.1 171.8 ± 84 0.19 0.12
Total cholesterol 174.6 ± 39.4 201.4 ± 39.5 0.001* 0.001*
HDL cholesterol 40.7 ± 8.9 45.9 ± 11.7 0.01* 0.01*
LDL cholesterol 94.9 ± 23.8 113.9 ± 24.8 0.001* 0.001*
Serum
creatinine (mg/dl)
1.0 ± 0.2 0.9 ± 0.2 0.45 0.29
eGFR
(ml/min/1.73 m2)





RBP4 (µg/ml) 71.9 ± 35.6 80.7 ± 31.6 0.15 0.21
Totala
adiponectin (µg/ml)
6.6 ± 3.4 6.62 ± 2.8 0.82 0.72
HMWa
adiponectin (µg/ml)
3.7 ± 1.9 3.50 ± 1.7 0.90
CIMT (mm) 0.8 ± 0.2 0.66 ± 0.2 0.001* 0.04*
ABI 1.1 ± 0.1 1.2 ± 0.1 0.015 0.97
Medication




Statin (n) (%) 43 (42.5) -
Aspirin (n) (%) 46 (45.5) -
BMI, body mass index ;SBP, systolic blood pressure; DBP, diastolic blood
pressure; FPG, fasting plasma glucose; HOMA-IR homeostasis model
assessment of insulin resistance; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; eGFR, estimated glomerular filtration rate ; RBP4, retinol-
binding protein 4; HMW, high molecular weight adiponectin; C IMT, carotid
intima-media thickness. ABI, ankle brachial pressure index.
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assay CV for total adiponectin was 7.5% and the inter-
assay was 6.25%. The measured intra-assay CV for low,
moderate and high range of HMW adiponectin were
1.02%, 2.68% and 2.62%, respectively, and the inter-assay
were 4.1%, 7.2% and 4.03%, respectively.
CIMT was measured by B- mode ultrasonography
which was equipped with a 13 MHZ linear transducer
and performed by 2 expert radiologists for all partici-
pants. Patients were in the supine position with a lit-
tle hyper extension and rotation of the neck to the
opposite side. The measurements were acquired from
three segments including common carotid artery
(CCA), carotid bifurcation and internal carotid artery
on both left and right sides posteriorly and anteriorly
at the end of diastolic phase. The CIMT was mea-
sured at the far wall on each carotid segment on both
sides as the distance between the interface of the
lumen and intima, and the interface between the
media and adventitia. The average value of CIMT
measurements of twelve locations was expressed as
mean CIMT.
Statistics analysis
Normality assumption of variables was defined by
Kolmogorov-Smirnov test and then the comparison be-
tween groups mean differences was performed by stu-
dent’s t test. Normal distributed data are expressed as the
mean ± SD. Because of skewed distribution, adiponectin
and CIMT concentration were logarithmically trans-
formed. The relationship between CIMT and adipokines
was tested by using the spearman correlation and regres-
sion models. Univariate analysis of baseline clinical,
metabolic markers, and serum adipokines including
age, sex, smoking, BMI, waist circumference, blood
pressure, fasting glucose, triglyceride, total cholesterol,
HDL and LDL cholesterol, serum creatinin. RBP4 and
total and HMW adiponectin and ABI was performed
separately in diabetic and control groups. Subsequently,
risk factors with a significant P-value (<0.05) were
included in a linear multiple regression model to deter-
mine independent predictors of CIMT. The SPSS 11.5
statistical software package (SPSS Inc. Chicago) was ap-
plied for all calculations. A 5% or lower p-value is consid-
ered statistically significant
Results
Clinical characteristics of patients
The clinical and metabolic features of variables belonging
to diabetic patients and controls and also information
about the number of subjects taking any medication were
shown in Table 1.
According to the t test the diabetic patients were older
and had significantly higher levels of serum FBS, HbA1Cand HOMA index as expected, whereas serum total chol-
esterol, HDL and LDL cholesterol were significantly higher
in control group.
The mean concentration of RBP4 and total and HMW
adiponectin did not differ between two groups. CIMT
Figure 1 Scatterplot of Carotid intima media thickness and serum concentration of RBP4 (A) and total adiponectin (B).
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0.66 ± 0.16 p = 0.001] while ABI was significantly higher
in control group (1.11 ± 0.10 vs. 1. 16 ± 0.11 p = 0.015).
To reduce the effect of age which were significantly
higher in diabetic group, age adjusted analysis were per-
formed but it did not modify our significant findings ex-
cept for ABI which did not remain significant anymore
between the two groups (Table 1).
The association of CIMT with RBP4 and total and HMW
adiponectin
No significant relationship was observed between CIMT
and RBP4 (r = 0.008 p >0.05) or total (r = 0.125 p >0.05)and HMW adiponectin (r = 0.109 p >0.05) by using
spearman correlation (Figure 1). Linear regression ana-
lysis was also performed with CIMT as dependent vari-
able and adipokines and cardio metabolic risk factors as
independent variables.
As shown in Table 2, age, waist circumference, TG
were identified as independent predictors for CIMT
while RBP4 and adiponectin were not potential predictor
of CIMT neither in diabetic group nor in control group.
Even though ABI tended to have negative association
with CIMT, but it still did not reach to significant level.
Importantly in multivariate model, age, blood pressure
and triglyceride were the main predictors of CIMT.
Table 2 The relationship between CIMT and RBP4, total and HMW adiponectin and other cardio metabolic risk factors
as independent variable
Diabetic group Control group
Univariate Multivariate Univariate
Variable Standard B coefficient P value Standard B coefficient P value Standard B coefficient P value
Age 0.44 0.01 0.328 0.001 0.35 0.01
Sex −0.11 0.23 - - −0.21 0.18
Smoking 0.07 0.43 - - 0.15 0.82
Blood pressure 0.37 0.01 0.246 0.006 0.16 0.33
Waist circumference −0.21 0.03 −0.219 0.010 0.002 0.981
BMI −0.13 0.18 - - −0.16 0.31
FPG −0.07 0.45 - - −0.04 0.48
Creatinine 0.11 0.23 - - 0.04 0.76
Triglyceride 0.12 0.05 0.243 0.007 −0.02 0.82
Total -C 0.15 0.18 - - 0.05 0.71
HDL-C −0.01 0.87 - - 0.09 0.54
LDL-C 0.14 0.1 - - −0.10 0.53
RBP4 −0.06 0.54 - - −0.2 0.20
Total Adiponectin −0.07 0.58 - - −0.06 0.88
HMW Adiponectin 0.07 0.53 - - −0.08 0.07
ABI −0.1 0.07 - - −0.008 0.96
BMI, body mass index; FPG, fasting plasma glucose; HDL, high-density lipoprotein; LDL, low-density lipoprotein; RBP4, retinol-binding protein 4; HMW, high
molecular weight adiponectin; ABI,ankle brachial pressure index.
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In this study we evaluated the association of CIMT, an
established marker of subclinical atherosclerosis, with
RBP4 and total and HMW adiponectin in type 2 diabetic
patients without clinical evidence of atherosclerotic vas-
cular disease. We found that the CIMT in diabetic group
was significantly higher compared to non-diabetic group.
This finding is in agreement with previous study that
reported the chronic hyperglycemia in diabetic patients
could induce athrogenesis by increasing oxidative stress
and decreased nitric oxide bioavailability [9]. It is well
known that the risk of atherosclerosis is much higher in
diabetic patients and suggested that, in response to dia-
betes the endogenous defense of the vascular endothelium
begins to break down [20]. The main finding of our study
is that, the CIMT did not show a significant relationship
with total or HMW adiponectin in a univariate regression
analysis. Our result is inconsistent with some previous
studies reported an inverse correlation between adiponectin
levels and CIMT in non-diabetic subjects including middle
aged healthy women [21], obese children [22] and healthy
middle age males [23]. A negative correlation has also been
shown between HMW adiponectin level and CIMT in
obese and normal weight adolescents [24]. However the
lack of correlation between CIMT and adiponectin has also
been shown in healthy males [25] and middle–aged non
diabetic women [26].Taking together, it seems that the reported associ-
ation of CIMT with total and HMW adiponectin is
stronger in normal adults and obese children than in
diabetic patients.
Regarding to RBP4, in multivariable analysis, adjusted
for known risk factors which affect on CIMT, no in-
dependent association between CIMT and this adipo-
kine was found. In the literature, there are several
controversial reports regarding association between
CIMT and RBP4. For example, Ingelsson et al. [27]
assessed the relation between RBP4 and CIMT in
healthy elderly subjects and found an inverse correl-
ation of RBP4 with intima- media and plaque echo-
genicity. However, more recent data do not confirm
those findings in T2DM. In a study performed in type
2 diabetic patients by Takebayashi and his colleagues
[28], the CIMT showed no association with RBP4.
Lack of correlation between CIMT and RBP4 has also
been reported in a recent published article performed
on newly diagnosed un-treated type 2 diabetes [29].
The possible reasons for not finding significant asso-
ciation between CIMT and adipokines in our study
are explained below. Measurements of CIMT could
reflect the vascular structural changes including in-
timal lesion and medial hypertrophy [30] due to past
long term exposure to risk factors [31]. While it could
have been the biological effect of these adipokines
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some evidences showed that these adipokines may act as
determinant of the early functional change of the vascular
system [8]. Endothelial dysfunction occurs during the
early stages of atherosclerosis and is responsible for the
pathophysiological changes leading to subclinical athero-
sclerosis determined by CIMT [32]. Endothelial dysfunc-
tion resulted from decreased production or availability of
NO which is the key factor playing an essential role in the
regulation of vascular function [33,34].
The result of the study performed by Beauloye et al. [8]
showed that adiponectin level were independently asso-
ciated with increased IMT and they suggest that adiponec-
tin may play an early role in the pathophysiology of
atherosclerosis. Established by in vitro studies, adiponectin
serves to protect against the onset of endothelial dysfunc-
tion by promoting NO generation [35]. Conversely RBP4
may affect endothelial function directly through inhibition
of insulin mediated pathway for nitric oxide production in
endothelial cells [29,36].
Moreover some studies showed, adiponectin inhibits
expression of adhesion molecules which induces the pro-
gression of atherosclerosis [37,38]. In contrast a positive
correlation between RBP4 and several soluble adhesion
molecules are reported [28]. In addition some studies sug-
gested that RBP4 might be responsible for up regulation of
endothelial adhesion molecules and development of vascu-
lar complication [30,39,40].
Based on these evidences it seems these adipokines are
more related to the markers which induce early stages of
vascular changes than established structural changes
reflected by CIMT. While the mean duration of diabetes in
this study population was nearly nine years (Table 1) and it
is not known for how long the patients have been exposed
to this major risk factor prior to the confirmed diabetes
diagnosis. Therefore, further studies on young adult who
are prone or newly exposed to diabetes, are needed to de-
termine whether the serum levels of these adipokines could
act as plasma markers to predict vascular thickness.
Another reason for not finding this association is that,
many diabetic patients in this study were taking a range of
medication that might affect the CIMT measurements,
serum level of adipokines and on the relationship between
them.
In our study, CIMT showed a significant and positive cor-
relation with age and systolic blood pressure and triglycer-
ide but it did not show a significant relation with any of
metabolic markers including fasting glucose, insulin and
lipid markers.
The lack of association between CIMT and fasting glu-
cose, insulin and lipid markers has been reported by
previous investigators [15,41] and could be explained at
least partially by taking into account the role of anti-hyperglycemic and anti-hyperlipidemic medications con-
sumed by diabetic patients.
In conclusion, the present study showed that serum levels
of RBP4 or total and HMW adiponectin were not potential
predictors of CIMT, which reflects vascular structural
changes, in type 2 diabetic patients who exposed to this risk
factor at least for nine years.
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